14^th International Conference on Pharmaceutical Education and Practice October 28-28, 2022 Vancouver, Canada

Biography:

Abstract:

Biography:

Laila M. Montaser MD is a distinguished Prof. of Clinical Pathology. She served as the Chair Emeritus, Founder leader of Clinical Pathology Department, Faculty of Medicine, Menoufia University, Egypt. Montaser is an internationally recognized stem cell technology professional.  She has key competence in stem cell technology and regenerative medicine policy reinforced by global level and international experience in research, formulation and capacity building.  In the era of COVID-19, she was awarded twenty one certificates of appreciation for successfully presenting thirty seven Global Webinars 21/37 (56.8%) from her home office amid the lock-down of COVID-19 crisis.

Abstract:

COVID-19 has proved fatal to countless people with a compromised immune system. Similar to the principle mechanisms in treating autoimmune diseases, Stem cell therapy aims to reset and strengthen the compromised immune systems and thereby reduce the high mortality rate among severe COVID-19 patients. Mesenchymal stem cells (MSCs) are the most scientifically studied cells in regenerative medicine, owing to their immunomodulatory and differentiation potential. However, several complications come with their translational application like viability, duration, and degree of expansion, long-term storage, and high maintenance cost. Therefore, drawbacks of cell-based therapy can be overcome by a novel therapeutic modality emerging in translational research and application, i.e., exosomes. Application of MSC derived exosomes has been presented in drug delivery, which has made these Nano-vesicles an attractive clinical tool. The vast advantages of using exosomes over MSCs have shifted the focus on these Nano-platforms. The MSCs derived exosomes can be a novel intervention for treating the current COVID-19 pandemic situation due to their regenerative, immunomodulatory, and antimicrobial properties. With upcoming reports and clinical studies using these proposed novel therapeutic interventions, exosomes can be established as cell-free therapeutics and drug delivery modality worldwide. This is the need of the hour and must be looked into as a potential Nano-intervention for treating critically ill patients. This paper displays such a diverse range of advantageous properties including their spectral curability, and their capability to be used as a drug carrier, make exosomes an ideal candidate for clinical applications, and as an off the shelf therapeutics.

Biography:

(Dr.) Joelle Nohra completed her PharmD in pharmaceutical sciences from Saint Joseph University and has three master’s degrees, one in marketing from  Montpellier University, one in Health Management from Paris University, and an Executive Master in Business Administration from ESCP Europe. From one achievement to the other in the pharmaceutical field, she was able to meet her commitments and leverage the brand equity of the products in charge. Today, she is responsible for the Global Brand Management and the Social Media Marketing Management in LSI Silderma LTD, a pharmaceutical dermo-cosmetic company based in Ireland and operating worldwide. 

Abstract:

In recent times, the permanent growth of online and digital marketing as a means of communicating with and selling to consumers has drastically modified the new rules of doing business. Both marketing and consumer behavior have grown and changed substantially as consumers spend more time and money on internet channels. Nowadays, consumers are playing a more explicit and larger role in any product’s failure or success.

The pharmaceutical industry cannot be set apart from any recent changes, especially the digital transformation which is one of the biggest changes in our actual landscape. Since 2010, the digital health market has tremendously grown and Covid-19 has greatly accelerated digital transformation in the pharmaceutical industry. While respecting the regulatory constraints in the different markets,  it really matters to understand what the digital transformation means for the pharmaceutical sector, what such a digital valuable asset has to bring to companies, and how the latest can rely on it and embed it to serve as a competitive edge they can rely on to differentiate themselves in a crowded environment.

However, despite all the advantages digital marketing is offering to pharmaceutical companies, still, it is a double-edged sword that marketers should wield properly to serve their companies’ growth and reputation.

Biography:

Obaid Ali, a graduate of Biological Sciences and Bachelor of Pharmacy earned his MPhil in Neuropharmacology and completed his Ph.D. in Pharmaceutical Chemistry. He served Government of Pakistan as a Civil Service Officer in Drug Regulatory Authority of Pakistan for more than two decades on different key leading positions. He was an alumni of international regulatory forums of CDER, US-FDA and HPFB, Health Canada. He was a Training Consultant of WHO and completed his assignments in different countries. He is on board of different academic institutions. 

Abstract:

Data is the active raw material for quality product that can deliver desired output every time consistently. Information is derived from data and experience of feelings convert data into knowledge that upon practice increase wisdom and keep decisions within sensible space. Integrity of the data and its connection with the object may not be understood if relation is not established between them. To know the unknowns and to understand them is indispensable in science and scientific conclusions. Use of reliable methods, appropriate approach in scientific experiments creates certainty and uphold promises. From testing reliability of pandemic to prevention through vaccine and treatment via chemical, biological and blood products are not proven strong enough to answer the concerns and questions already set in the 21^st century of pharmaceutical sciences. Multidisciplinary approach and open discussions on scientific methods used to develop and approve products among the scientific individuals are the only way to maintain grace of science and trust of common man. Focusing on expansion of learning space and feeling space in dynamic reshaping technological world can maintain the momentum of development and progress.

Biography:

Prof. T. R. Bhardwaj is renowned pharmaceutical academician, scientist and presently working as Advisor to Chancellor (Former Vice Chancellor), Baddi University of Emerging Sciences & Technology, Baddi. He has also been Dean, School of Pharmacy and Emerging Sciences since September, 2014. Prof. Bhardwaj has obtained M. Pharm. and Ph.D.  degrees from University Institute of Pharmaceutical Sciences (UIPS), Panjab University, Chandigarh and served his alma matter for around 32 years under various capacities such as Dean-Faculty of Pharmaceutical Sciences, Chairman-UIPS.  He has also been International Research Fellow, SRI-International (Formerly Stanford Research Institute), California, USA from August, 1988 to January, 1996 (around 4 years). Prof. Bhardwaj has 17 patents including 9 US patents and more than 200 publications in reputed International/National journals. He has guided 15 Ph.D. and 90 M. Pharm. Students. Dr. Bhardwaj is recipient of GP Srivastava Memorial Award, Association of Pharmaceutical Teachers of India, December, 2017, Teacher of Excellence Award, Golden Jubilee Celebrations, APTICON 2016 and recently has received ET (Economic Times) Inspiring Leaders Award in Education in December, 2021.

Abstract:

India has emerged as global health provider, having expertise in manufacturing of generics. This drug industry flourished after the passage of the Drug Price Competition and Patent Term Restoration Act of 1984. Fifty years later, the generic drug industry has achieved remarkable success in getting affordable medicines to patients. The generic products typically cost 50 to 70 percent less than their brand-name counterparts-while meeting the very same standards for safety, quality, and effectiveness as innovator drugs. Global pharmaceutical market is undergoing rapid transformation. The products manufactured by the Indian pharmaceutical industry can be broadly classified into active pharmaceutical ingredients and formulations. India is one among the largest API manufacturers in terms of volume and value. Out of the total number of pharmaceutical manufacturers, about 77% produce formulations and remaining 23% manufacture bulk drugs. In 2001, CIPLA introduced the world first ever recommended fixed dose combination (Stavudine + Lamivudine + Neviropine) to fight AIDS. It was made available at less than $1 per day compared to over $12,000 per patient per year prevailing in most countries.

The UN Secretary-General, Antonio Guterres has applauded India for supplying COVID-19 doses to nations around the world to combat the catastrophic global health crisis. India has played a major role in ensuring a global vaccination to fight the pandemic. Guterres said, “I would like to say how much we count on India, I mean, India has one of the most advanced pharmaceutical industries. India played a very important role in the production of generics for use that was a very important element of democratisation all over the world”. Taking into consideration the above mentioned India’s potential and capabilities with respect to global healthcare, opportunities, challenges and their impacts on pharmaceutical education will be discussed.

Biography:

Raweesh Chaudhary is a pharmacist and an MBA with over 27 years in the pharmaceutical insdustry spread across three different countries and two different continents, in multiple roles with progressive responsibilities (Product management, field based commercial and medical roles and  strategic medical director roles). Raweesh currently works as a strategy director of Medical Excellenc at Biogen inc. Based out of USA.This presentation is Raweesh’s personal opinion and he is not speaking on behalf of Biogen.

Abstract:

Digital technology has emerged as a powerful solution enabler of three major confounders of pharma industry’s scientific communication problems: (a) Proximity of the communicators (b) Synchronicity at the time of communication and (c) Amplification of the message.

However as messaging becomes more amplified, asynchronous and proximity independent, it has an inverse effect on message clarity and personalization that often leads to lack of credibility of the message.

This presentation aims to define the changing OMNICHANNEL communication landscape, as it applies to the Pharmaceutical industry, identify various communications tools available within each channel and attempts to define strategies on customer preference to specific types of channels aligned to their particualar communication needs.

It will also make the case that, it is not the availability of technological solutions within each channel that should define how we communcate with our scientific peers, rather the preference and appropriateness of the tools available, to the people we are communicating with.

The presentation will also discuss strtrategies on how to diffrentiate between Virtual platforms (which are often just surrogate for realtime physical presence) and true Digital platforms which are both independent of geographical proximity and time, as it applies to  Pharmaceutical communication.

The presentation will finally make the case that, the focus of Digital transformation in the context of the Pharmaceutical industry, should be on Transformation of PEOPLE to accept digital technology rather than the transformation of technology itself.

Biography:

Jeanne Moldenhauer has extensive experience in pharmaceuticals and medical devices.  She has worked in microbiological development, contamination control, quality, regulatory, aseptic processing, sterilization, sterile process validation, and compliance.  Her major area of study in college and graduate school was microbiology and virology.  She serves as the Chief Science Officer of C-POLAR Technologies, Inc. and also consults with the pharmaceutical industry.  She has published more than 40 technical books through PDA-DHI and CRC Press.  She has also published more than 100 articles.  She has served on the scientific advisory board, and the regulatory affairs and quality advisory board of the Parenteral Drug Association (PDA).

Abstract:

With the most recent update of the European Union’s (EU) Annex 1 to the GMPs for Manufacture of Sterile Products, there is an increased focus by regulatory agencies on the contamination control practices used in facilities.  While many companies chose to focus on traditional methodologies, there are many new technologies that greatly exceed the potentials available with new technologies. This talk will focus on some new technologies which can be used to improve older methods for contamination control.  For example, new filtration systems that can eliminate viruses and microorganisms will be discussed.  This filtration technology has been adapted to provide many different applications in clean rooms and hospitals. Consider the possibilities of improving the health of your employees and protecting your products from many more contaminants than in the past.  Many of these products have been developed utilizing an international consortium of researchers.